CoChat
Sign Up
Cited by 429Pancreatic and Hepatic Oncology ResearchCholangiocarcinoma and Gallbladder Cancer StudiesNeuroendocrine Tumor Research Advances

The DOI matches its Crossref record; 82 of the 95 references it cites were found in a registry or an index.

Multicomponent Analysis of the Pancreatic Adenocarcinoma Progression Model Using a Pancreatic Intraepithelial Neoplasia Tissue Microarray

Open access
Maitra, Anirban, Adsay, N Volkan, Argani, Pedram, Iacobuzio-Donahue, Christine, De Marzo, Angelo, Cameron, John L, Yeo, Charles J, Hruban, Ralph H·2003·Modern Pathology
DOI 10.1097/01.mp.0000086072.56290.fb
Open this paper in CoChat — free account

Abstract

A multistep model for pancreatic adenocarcinoma has been proposed recently. In this model, well-defined, noninvasive ductal lesions are recognized as precursors of invasive cancer and have been classified under the nomenclature of pancreatic intraepithelial neoplasia, or PanIN. Increasing evidence suggests that PanINs represent true neoplasms of the pancreatic ductal epithelium, accumulating histologic and genetic abnormalities in their progression toward invasive cancer. We have constructed a tissue microarray containing 55 PanIN lesions of all histologic grades in order to perform a multicomponent analysis of the pancreatic adenocarcinoma progression model. The protein products of 14 genes encompassing a variety of functional classes, such as tumor suppressor genes (p53, Smad4/Dpc4), oncogenes (beta-catenin), cell cycle antigens (p16, cyclin D1), proliferation antigens (Ki-67, topoisomerase II alpha), and epithelial apomucins (MUC1, MUC2, MUC5), as well as "novel" genes described as differentially up-regulated in invasive pancreas cancer by global microarray expression analysis (mesothelin, prostate stem cell antigen, fascin, and 14-3-3varsigma), were analyzed by immunohistochemistry on the PanIN tissue microarray. Comparison of the results from the current study with previously published data performed on routine histologic sections of PanINs demonstrates that tissue microarrays are a valid platform for molecular analysis not only of invasive cancers but of precursor lesions as well. In addition, this study demonstrates that molecular abnormalities in PanINs are not random but can usually be stratified into "early" changes (e.g., expression of MUC5 and prostate stem antigen, or loss of p16), "intermediate" changes (e.g., expression of cyclin D1), and "late" changes (e.g., expression of p53, proliferation antigens, MUC1, mesothelin, and 14-3-3varsigma, or loss of Smad4/Dpc4). Understanding the molecular pathogenesis of precursor lesions of invasive pancreatic adenocarcinomas using a high-throughput tissue microarray-based approach is a valuable adjunct to designing rational strategies for early detection of this lethal neoplasm.

Overview

Integrity signals

Registry

Crossref · 10.1097/01.mp.0000086072.56290.fb

Cites

82 of 82 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 95 references

Cited by

Sorted by citations

Items 401–425 of 425

Related

See all

Metadata

Authors
Maitra, A., Adsay, N. V., Argani, P., Iacobuzio-Donahue, C., De Marzo, A., Cameron, J. L., Yeo, C. J., & Hruban, R. H.
Affiliations
Johns Hopkins University (US)
Corresponding author
Maitra, Anirban
ORCID
Venue
Modern Pathology
Publisher
Elsevier BV
Published
2003-09
Volume
16
Issue
9
Pages
902-912
ISSN
0893-3952 (ISSN-L)
DOI
10.1097/01.mp.0000086072.56290.fb
OpenAlex
W1980447806
Cited by
429
References
95
Citations by year
2026: 12 · 2025: 12 · 2024: 13 · 2023: 18 · 2022: 11 · 2021: 16 · 2020: 11 · 2019: 14 · 2018: 24 · 2017: 16 · 2016: 13 · 2015: 16 · 2014: 22 · 2013: 19 · 2012: 24
FWCI
8.71
Type
journal article
Language
en
Open access
Licence
Locations
  • Modern Pathology (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Cancer Institute (P50CA-62924, P50CA062924)
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
  • Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
Keywords
pancreatic ductal adenocarcinoma, pancreatic intraepithelial neoplasia, tumor progression, precursor lesions, tissue microarray, molecular pathogenesis, p53, β-catenin, p16, cyclin D1, Ki-67, TOP2A, MUC1, MUC2, mesothelin, prostate stem cell antigen, fascin, 14-3-3 sigma, early detection
MeSH terms
Adenocarcinoma, Carcinoma in Situ, DNA, Neoplasm, Humans, Immunohistochemistry, Pancreatic Neoplasms, Precancerous Conditions, Biomarkers, Tumor, Disease Progression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review